tiprankstipranks
United Therapeutics (UTHR)
NASDAQ:UTHR
US Market
UTHR
United Therapeutics
RESEARCH TOOLSreports

United Therapeutics (UTHR) Stock Forecast & Price Target

699 Followers
See the Price Targets and Ratings of:

UTHR Analyst Ratings

Moderate Buy
13Ratings
Moderate Buy
9 Buy
4 Hold
0 Sell
Based on 13 analysts giving stock ratings to
United
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

UTHR Stock 12 Month Forecast

Average Price Target

$621.50
▲(10.04% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for United Therapeutics in the last 3 months. The average price target is $621.50 with a high forecast of $705.00 and a low forecast of $471.00. The average price target represents a 10.04% change from the last price of $564.81.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"289":"$289","706":"$706","393.25":"$393.3","497.5":"$497.5","601.75":"$601.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":705,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$705.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":621.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$621.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":471,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$471.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[289,393.25,497.5,601.75,706],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,570.27,580.6338461538461,590.9976923076923,601.3615384615384,611.7253846153847,622.0892307692308,632.4530769230769,642.8169230769231,653.1807692307692,663.5446153846153,673.9084615384616,684.2723076923077,694.6361538461539,{"y":705,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,570.27,574.2107692307692,578.1515384615384,582.0923076923077,586.0330769230769,589.9738461538461,593.9146153846153,597.8553846153847,601.7961538461539,605.7369230769231,609.6776923076923,613.6184615384616,617.5592307692308,{"y":621.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,570.27,562.6338461538461,554.9976923076923,547.3615384615384,539.7253846153847,532.0892307692308,524.4530769230769,516.8169230769231,509.1807692307692,501.5446153846154,493.90846153846155,486.27230769230766,478.63615384615383,{"y":471,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":306.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":293.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325.48,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":290.91,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":294.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":404.81,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":438.18,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":445.43,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":479.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":487.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":475,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 84,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":513.82,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 112,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":570.27,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 98,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$705.00Average Price Target$621.50Lowest Price Target$471.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on UTHR
Tiago Fauth
Wells Fargo
Wells Fargo
$650→$575
Hold
1.80%
Upside
Reiterated
04/01/26
United Therapeutics price target raised to $575 from $486 at Wells FargoUnited Therapeutics price target raised to $575 from $486 at Wells Fargo
H.C. Wainwright Analyst forecast on UTHR
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$600→$660
Buy
16.85%
Upside
Reiterated
03/30/26
United Therapeutics price target raised to $660 from $600 at H.C. WainwrightUnited Therapeutics price target raised to $660 from $600 at H.C. Wainwright
Bank of America Securities Analyst forecast on UTHR
Jason Gerberry
Bank of America Securities
Bank of America Securities
$569→$626
Hold
10.83%
Upside
Reiterated
03/30/26
Balanced View on Tyvaso’s IPF Upside: Strong Phase 3 Momentum Offset by Valuation and Execution Risks
TD Cowen Analyst forecast on UTHR
Joseph Thome
TD Cowen
TD Cowen
$575→$660
Buy
16.85%
Upside
Assigned
03/30/26
United Therapeutics price target raised to $660 from $575 at TD CowenUnited Therapeutics price target raised to $660 from $575 at TD Cowen
Morgan Stanley Analyst forecast on UTHR
Terence Flynn
Morgan Stanley
Morgan Stanley
$471
Hold
-16.61%
Downside
Reiterated
03/30/26
Analysts Are Neutral on Top Healthcare Stocks: Gilead Sciences (GILD), United Therapeutics (UTHR)
Jefferies Analyst forecast on UTHR
Roger Song
Jefferies
Jefferies
$640→$668
Buy
18.27%
Upside
Assigned
03/30/26
Jefferies sees 15%-25% move in United Therapeutics after TETON-1 study hitsJefferies sees 15%-25% move in United Therapeutics after TETON-1 study hits
RBC Capital Analyst forecast on UTHR
Lisa Walter
RBC Capital
RBC Capital
$587→$643
Buy
13.84%
Upside
Assigned
03/30/26
RBC sees high probability of approval in IPF after United's TETON-1 clears barRBC sees high probability of approval in IPF after United's TETON-1 clears bar
Oppenheimer Analyst forecast on UTHR
Andreas Argyrides
Oppenheimer
Oppenheimer
$600→$650
Buy
15.08%
Upside
Reiterated
03/12/26
Oppenheimer Keeps Their Buy Rating on United Therapeutics (UTHR)
Cantor Fitzgerald Analyst forecast on UTHR
Unknown Analyst
Cantor Fitzgerald
Not Ranked
Cantor Fitzgerald
$525→$625
Buy
10.66%
Upside
Initiated
03/12/26
Cantor Fitzgerald Reaffirms Their Buy Rating on United Therapeutics (UTHR)
UBS Analyst forecast on UTHR
Ashwani Verma
UBS
UBS
$655→$705
Buy
24.82%
Upside
Assigned
03/05/26
Analysts Conflicted on These Healthcare Names: Veeva Systems (NYSE: VEEV) and United Therapeutics (NASDAQ: UTHR)
Argus Research Analyst forecast on UTHR
Jasper Hellweg
Argus Research
Argus Research
$560
Buy
-0.85%
Downside
Assigned
03/03/26
United Therapeutics price target raised to $560 from $500 at ArgusUnited Therapeutics price target raised to $560 from $500 at Argus
Leerink Partners Analyst forecast on UTHR
Roanna Ruiz
Leerink Partners
Leerink Partners
$600→$615
Buy
8.89%
Upside
Reiterated
03/02/26
United Therapeutics price target raised to $615 from $600 at LeerinkUnited Therapeutics price target raised to $615 from $600 at Leerink
BTIG Analyst forecast on UTHR
Julian Harrison
BTIG
BTIG
―
Hold
―
Reiterated
02/25/26
Balancing Franchise Headwinds and Pipeline Upside: Rationale Behind a Hold on United Therapeutics
J.P. Morgan Analyst forecast on UTHR
Jessica Fye
J.P. Morgan
J.P. Morgan
$345→$450
Buy
-20.33%
Downside
Reiterated
09/09/25
United Therapeutics (UTHR) Receives a Buy from J.P. Morgan
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on UTHR
Tiago Fauth
Wells Fargo
Wells Fargo
$650→$575
Hold
1.80%
Upside
Reiterated
04/01/26
United Therapeutics price target raised to $575 from $486 at Wells FargoUnited Therapeutics price target raised to $575 from $486 at Wells Fargo
H.C. Wainwright Analyst forecast on UTHR
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$600→$660
Buy
16.85%
Upside
Reiterated
03/30/26
United Therapeutics price target raised to $660 from $600 at H.C. WainwrightUnited Therapeutics price target raised to $660 from $600 at H.C. Wainwright
Bank of America Securities Analyst forecast on UTHR
Jason Gerberry
Bank of America Securities
Bank of America Securities
$569→$626
Hold
10.83%
Upside
Reiterated
03/30/26
Balanced View on Tyvaso’s IPF Upside: Strong Phase 3 Momentum Offset by Valuation and Execution Risks
TD Cowen Analyst forecast on UTHR
Joseph Thome
TD Cowen
TD Cowen
$575→$660
Buy
16.85%
Upside
Assigned
03/30/26
United Therapeutics price target raised to $660 from $575 at TD CowenUnited Therapeutics price target raised to $660 from $575 at TD Cowen
Morgan Stanley Analyst forecast on UTHR
Terence Flynn
Morgan Stanley
Morgan Stanley
$471
Hold
-16.61%
Downside
Reiterated
03/30/26
Analysts Are Neutral on Top Healthcare Stocks: Gilead Sciences (GILD), United Therapeutics (UTHR)
Jefferies Analyst forecast on UTHR
Roger Song
Jefferies
Jefferies
$640→$668
Buy
18.27%
Upside
Assigned
03/30/26
Jefferies sees 15%-25% move in United Therapeutics after TETON-1 study hitsJefferies sees 15%-25% move in United Therapeutics after TETON-1 study hits
RBC Capital Analyst forecast on UTHR
Lisa Walter
RBC Capital
RBC Capital
$587→$643
Buy
13.84%
Upside
Assigned
03/30/26
RBC sees high probability of approval in IPF after United's TETON-1 clears barRBC sees high probability of approval in IPF after United's TETON-1 clears bar
Oppenheimer Analyst forecast on UTHR
Andreas Argyrides
Oppenheimer
Oppenheimer
$600→$650
Buy
15.08%
Upside
Reiterated
03/12/26
Oppenheimer Keeps Their Buy Rating on United Therapeutics (UTHR)
Cantor Fitzgerald Analyst forecast on UTHR
Unknown Analyst
Cantor Fitzgerald
Not Ranked
Cantor Fitzgerald
$525→$625
Buy
10.66%
Upside
Initiated
03/12/26
Cantor Fitzgerald Reaffirms Their Buy Rating on United Therapeutics (UTHR)
UBS Analyst forecast on UTHR
Ashwani Verma
UBS
UBS
$655→$705
Buy
24.82%
Upside
Assigned
03/05/26
Analysts Conflicted on These Healthcare Names: Veeva Systems (NYSE: VEEV) and United Therapeutics (NASDAQ: UTHR)
Argus Research Analyst forecast on UTHR
Jasper Hellweg
Argus Research
Argus Research
$560
Buy
-0.85%
Downside
Assigned
03/03/26
United Therapeutics price target raised to $560 from $500 at ArgusUnited Therapeutics price target raised to $560 from $500 at Argus
Leerink Partners Analyst forecast on UTHR
Roanna Ruiz
Leerink Partners
Leerink Partners
$600→$615
Buy
8.89%
Upside
Reiterated
03/02/26
United Therapeutics price target raised to $615 from $600 at LeerinkUnited Therapeutics price target raised to $615 from $600 at Leerink
BTIG Analyst forecast on UTHR
Julian Harrison
BTIG
BTIG
―
Hold
―
Reiterated
02/25/26
Balancing Franchise Headwinds and Pipeline Upside: Rationale Behind a Hold on United Therapeutics
J.P. Morgan Analyst forecast on UTHR
Jessica Fye
J.P. Morgan
J.P. Morgan
$345→$450
Buy
-20.33%
Downside
Reiterated
09/09/25
United Therapeutics (UTHR) Receives a Buy from J.P. Morgan
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering United Therapeutics

3 Months
xxx
Success Rate
15/17 ratings generated profit
88%
Average Return
+15.95%
reiterated a xxx
 rating last month
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 88.24% of your transactions generating a profit, with an average return of +15.95% per trade.
1 Year
Roger SongJefferies
Success Rate
12/12 ratings generated profit
100%
Average Return
+33.53%
assigned a buy rating 7 days ago
Copying Roger Song's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +33.53% per trade.
2 Years
xxx
Success Rate
17/17 ratings generated profit
100%
Average Return
+70.47%
reiterated a xxx
 rating last month
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +70.47% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

UTHR Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
0
0
Buy
23
18
84
112
98
Hold
7
3
7
11
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
30
21
91
123
108
In the current month, UTHR has received 98 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. UTHR average Analyst price target in the past 3 months is 621.50.
Each month's total comprises the sum of three months' worth of ratings.

UTHR Financial Forecast

UTHR Earnings Forecast

Next quarter’s earnings estimate for UTHR is $7.00 with a range of $6.23 to $8.15. The previous quarter’s EPS was $7.70. UTHR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year UTHR has Performed in-line its overall industry.
Next quarter’s earnings estimate for UTHR is $7.00 with a range of $6.23 to $8.15. The previous quarter’s EPS was $7.70. UTHR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year UTHR has Performed in-line its overall industry.

UTHR Sales Forecast

Next quarter’s sales forecast for UTHR is $801.45M with a range of $771.09M to $844.00M. The previous quarter’s sales results were $790.20M. UTHR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year UTHR has Performed in-line its overall industry.
Next quarter’s sales forecast for UTHR is $801.45M with a range of $771.09M to $844.00M. The previous quarter’s sales results were $790.20M. UTHR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year UTHR has Performed in-line its overall industry.

UTHR Stock Forecast FAQ

What is UTHR’s average 12-month price target, according to analysts?
Based on analyst ratings, United Therapeutics’s 12-month average price target is 621.50.
    What is UTHR’s upside potential, based on the analysts’ average price target?
    United Therapeutics has 10.04% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is UTHR a Buy, Sell or Hold?
          United Therapeutics has a consensus rating of Moderate Buy which is based on 9 buy ratings, 4 hold ratings and 0 sell ratings.
            What is United Therapeutics’s price target?
            The average price target for United Therapeutics is 621.50. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $705.00 ,the lowest forecast is $471.00. The average price target represents 10.04% Increase from the current price of $564.81.
              What do analysts say about United Therapeutics?
              United Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of UTHR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.